Metabolic syndrome abating the beneficial effect of pravastatin treatment on adhesion of endothelium by monocytes in subjects with hypercholesterolemia

Metabolism: Clinical and Experimental

Volumn 58, Issue 3, 2009, Pages 416-420

  Lee, I Te ^a,b   Lee, Wen Jane ^a   Ou, Hsiu Chung ^a   Huang, Chien Ning ^b   Sheu, Wayne Huey Herng ^a,b  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ADULT; ARTICLE; CELL ADHESION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MEGADOSE; ENDOTHELIUM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; MALE; METABOLIC SYNDROME X; MOLECULAR INTERACTION; MONOCYTE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CELL ADHESION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MONOCYTES; PATIENT SELECTION; PRAVASTATIN; TRIGLYCERIDES; YOUNG ADULT;

EID: 59749105517     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.10.019     Document Type: Article

References (26)

1. Kharbanda R.K., and Deanfield J.E. Functions of the healthy endothelium. Coron Artery Dis 12 (2001) 485-491
2. Celermajer D.S. Endothelial dysfunction: does it matter? Is it reversible?. J Am Coll Cardiol 30 (1997) 325-333
3. Laroia S.T., Ganti A.K., Laroia A.T., and Tendulkar K.K. Endothelium and the lipid metabolism: the current understanding. Int J Cardiol 88 (2003) 1-9
4. Stokes K.Y., Cooper D., Tailor A., and Granger D.N. Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide. Free Radic Biol Med 33 (2002) 1026-1036
5. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326 (2003) 1423
6. Deedwania P., Barter P., Carmena R., Fruchart J.C., Grundy S.M., Haffner S., et al. Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368 (2006) 919-928
7. Wagner A.H., Gebauer M., Guldenzoph B., and Hecker M. 3-Hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler Thromb Vasc Biol 22 (2002) 1784-1789
8. Kawakami A., Tanaka A., Nakajima K., Shimokado K., and Yoshida M. Atorvastatin attenuates remnant lipoprotein-induced monocyte adhesion to vascular endothelium under flow conditions. Circ Res 91 (2002) 263-271
9. Ridker P.M., Rifai N., Pfeffer M.A., Moye L.A., Sacks F.M., Moye L.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98 (1998) 839-844
10. Rutter M.K., Meigs J.B., Sullivan L.M., D'Agostino Sr. R.B., and Wilson P.W. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110 (2004) 380-385
11. Yudkin Js J., Juhan-Vague I., Hawe E., Humphries Se S., Di Minno G., Margaglione M., et al. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 53 (2004) 852-857
12. Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Bonadonna R.C., et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 26 (2003) 1251-1257
13. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D.S., Haffner S.M., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
14. Lee W.J., Lee W.L., Tang Y.J., Liang K.W., Chien Y.H., Tsou S.S., et al. Early improvements in insulin sensitivity and inflammatory markers are induced by pravastatin in nondiabetic subjects with hypercholesterolemia. Clin Chim Acta 390 (2008) 49-55
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
16. Zimmet P., Magliano D., Matsuzawa Y., Alberti G., and Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 12 (2005) 295-300
17. Alberti K.G., Zimmet P., Shaw J., and IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
18. Friedwald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
19. Lee I.T., Sheu W.H., Lin S.Y., Lee W.J., Song Y.M., and Liu H.C. Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia. J Diabetes Complications 16 (2002) 382-385
20. Korlipara L.V., Leon M.P., Rix D.A., Douglas M.S., Gibbs P., Bassendine M.F., et al. Development of a flow cytometric assay to quantify lymphocyte adhesion to cytokine-stimulated human endothelial and biliary epithelial cells. J Immunol Methods 191 (1996) 121-130
21. Lee I.T., Lin T.M., Lee W.J., Ou H.C., Chien Y.H., Lee W.L., et al. Hypercholesterolemia, not metabolic syndrome, related to adhesion of monocytes to cultured endothelium in nondiabetic subjects. Metabolism. 54 (2005) 1467-1471
22. Jones P.H., Farmer J.A., Cressman M.D., McKenney J.M., Wright J.T., Proctor J.D., et al. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin Cardiol 14 (1991) 146-151
23. Saito Y., Goto Y., Nakaya N., Hata Y., Homma Y., Naito C., et al. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test. Atherosclerosis 72 (1988) 205-211
24. Rezaie-Majd A., Prager G.W., Bucek R.A., Schernthaner G.H., Maca T., Kress H.G., et al. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 23 (2003) 397-403
25. Martinez-Gonzalez J., Alfon J., Berrozpe M., and Badimon L. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 159 (2001) 27-33
26. Winkler K., Abletshauser C., Hoffmann M.M., Friedrich I., Baumstark M.W., Wieland H., et al. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab. 87 (2002) 5485-5490